News and alerts for US stocks

Know before your stocks move.

Most big moves start with a filing, a press release, an analyst call or an FDA decision. Quantisnow reads every one on US stocks and alerts you about 35ms after it publishes, with what it means for the stock.

from the source publishing to the alert on your phone
35msfrom the source publishing to the alert on your phone
bought by insiders this week
$165.3Mbought by insiders this week
scanner alerts last session
3,383scanner alerts last session
What we read
  • SEC EDGAR
  • Business Wire
  • GlobeNewswire
  • PR Newswire
  • Accesswire
  • FDA
  • Nasdaq halts
  • NYSE halts
  • FINRA short volume
  • Form 4 insider trades
  • 13F fund holdings
  • Analyst rating changes
  • 8-K and 6-K exhibits
  • XBRL financials

AI analysis

What each story means for the stock

Ellis, our AI agent, scores every filing and press release for impact, rates it bullish or bearish and writes what holders should know. 8,846 stories in the past seven days.

How the scoring works
Ellis's analysisVery bullishImpact 5/5

FDA Approval for KLYGEFA issued to ALEXION PHARM

The FDA approved Alexion Pharmaceuticals' Biologic License Application 761488 for KLYGEFA, a 600 MG solution for injection with the active ingredient gefurulimab, on 11/13/2026. The approval was for the original submission, and the marketing status is listed as prescription. The release does not say what condition the drug treats or how it performed in trials.

Approval date
11/13/2026
Strength
600 MG
Application number
761488

Good for holders

  • The FDA has approved KLYGEFA, moving the product to marketable prescription status.
Read the AZN story

News

This week's biggest stories

Ranked by how much each story could move its stock, with the key numbers pulled out of the filing or release. One story per company.

Open the feed
AstraZeneca PLC logo
AZNAstraZeneca ago
FDA

FDA Approval for KLYGEFA issued to ALEXION PHARM

The FDA approved Alexion Pharmaceuticals' Biologic License Application 761488 for KLYGEFA, a 600 MG solution for injection with the active ingredient gefurulimab, on 11/13/2026. The approval was for the original submission, and the marketing status is listed as prescription. The release does not say what condition the drug treats or how it performed in trials.

Approval date
11/13/2026
Strength
600 MG
Application number
761488
Nu Holdings Ltd. logo
NU ago

Q3 2026 net income hit record $1.1 billion, up 31% YoY

Nu Holdings reported third quarter 2026 results, with record gross revenue of $6.3 billion and record net income of $1.1 billion, both up sharply from a year earlier. Customer count reached 142.6 million and the credit portfolio grew to $41.6 billion, while efficiency improved to 19.3%. For a shareholder, the figures show strong growth in revenue, profit and lending, though the release notes that some delinquency measures worsened.

NVIDIA Corporation logo
NVDA ago

NVIDIA Announces CEO Transition

NVIDIA said CEO Jensen Huang has resigned from his roles as President, CEO and board member, effective immediately. CFO Colette Kress will serve as interim CEO while keeping her CFO role, and the board is searching for a permanent CEO. Harvey C. Jones was named the company's first-ever Chair of the Board, and the release says operations and the product roadmap are expected to continue without interruption.

Momentum

Momentum scanner

New highs and lows, fast moves and volume far above normal across every US stock, with the news behind each one. 3,383 alerts in the last session.

Open the scanner

Ellis

Ellis, your AI research assistant

Ellis reads the filings, pulls the prices and checks who has been buying, then gives you a short answer with its sources.

Meet Ellis

Ask Ellis about any stock

Ellis is our AI research assistant. It searches the news, filings, analyst calls and price history on Quantisnow and answers in plain English. More about Ellis

Smart money

Insiders, analysts and funds

Executives buying their own stock on the open market, analysts changing their rating, and where hedge funds moved money last quarter.

All insider trades

$165.3M

bought on the open market in the last 7 days by 321 officers, directors and large holders, in 369 purchases.

  1. Rehan JafferDirector
    Six Flags Entertainment Corporation/NEW logo
    FUN
    $14.9M
  2. Barry S SternlichtCEO
    Starwood Property Trust, Inc. logo
    STWD
    $14.7M
  3. Dylan G. HaggartDirector
    Stride, Inc. logo
    LRN
    $8.1M
  4. John F BarryCEO
    Prospect Capital Corp logo
    PSEC
    $6.1M
  5. Rtw Investments, LP10% owner
    Orchestra BioMed Holdings, Inc. logo
    OBIO
    $6.0M
  6. Sardar Biglari,CEO
    Biglari Holdings Inc. logo
    BH.A
    $5.5M
  7. Juniper Investment Company, LLC10% owner
    Orthofix Medical Inc. logo
    OFIX
    $5.1M
  8. Alfonso De AngoitiaDirector
    Liberty Latin America Ltd. logo
    LILAK
    $5.1M

Calendar

Earnings, dividends and listings

Results released this week, dividends declared with their dates, and the newest companies on the exchange.

Earnings

Plans

Pricing

Every plan reads the same wire. Plans differ in speed, alerts and how many stocks you follow.

Compare every feature

Free

The whole wire, 55 seconds behind. No card needed.

$0/ month
News speed55 sec late
  • Every story on the wire, 55 seconds late
  • Follow up to 5 tickers
  • Email alerts on those tickers, 55 seconds late
  • AI impact score and rating on every story, written analysis on most
  • 7 questions a day to the assistant

Core

Email and push alerts on 25 tickers, 25 seconds behind Plus.

$19/ month
News speed25 sec late
  • News 25 seconds behind, not 55 seconds
  • Follow up to 25 tickers
  • Email alerts on every ticker you follow
  • Push alerts on your phone
  • Halt alerts on the tickers you follow
  • 30 questions a day to the assistant

Card required. Free for 3 days, then $19/mo unless you cancel first. Payments are non-refundable.

Picked by most traders

Plus

Real-time alerts, 250 followed tickers, full history.

$69/ month
News speedImmediate
  • Every story the moment it posts, no delay
  • Follow up to 250 tickers
  • Live email and push alerts
  • Halt, earnings, insider buy and dividend alerts on any stock
  • AI summary on every story in the feed
  • Float, volume and impact filters
  • Full news archive and keyword price-impact finder

Card required. Free for 3 days, then $69/mo unless you cancel first. Payments are non-refundable.

Premium

Everything in Plus, delivered into your own systems.

$420/ month
News speedImmediate
  • Everything in Plus
  • Follow up to 500 tickers
  • Webhooks to your own endpoints
  • Up to 5 webhook URLs
  • Slack and Discord delivery
  • JSON payload per matching item

Core and Plus start with a 3-day free trial, one per account. Cancel any time in settings. Subscriptions are non-refundable, monthly or yearly. Compare every feature

About

About Quantisnow

Where the data comes from, how fast it reaches you, and who builds it.

What is Quantisnow

Quantisnow reads every SEC filing, press release, analyst call, FDA decision, insider trade and trading halt on US stocks as it is published, tags it to the companies it is about, and sends it to you. On Plus, an alert reaches you about 35ms after the source publishes. On Free, the same wire runs 55 seconds behind.